Immix Biopharma (IMMX) Other Accumulated Expenses (2020 - 2026)
Immix Biopharma (IMMX) reported Other Accumulated Expenses of $45,772 for Q2 2026, down 13.5% from $52,940 a year earlier and down 76.4% from the prior quarter.
Powered by 
Analysis
Immix Biopharma (IMMX) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
At the end of FY2025, Immix Biopharma posted Other Accumulated Expenses of $331,801, up 156.1% from FY2024.
- Other Accumulated Expenses has a five-year compound annual growth rate of -0.7% (FY2020 to FY2025).
- By year, Other Accumulated Expenses came in at $129,567 in FY2024 (+28.3%), $101,007 in FY2023 (-76.9%), $438,196 in FY2022 and $9,099 in FY2021 (-97.3%).
- The Q2 2026 figure ranks as the lowest quarterly Other Accumulated Expenses since Q3 2024.
- Year over year, Other Accumulated Expenses gained in five of the last eight quarters, with growth averaging 55.3%.
- The high point for year-over-year Other Accumulated Expenses in five years was Q3 2025 (growth of 294.3%); the low point was Q4 2021 (a decline of 97.3%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $193,715 (Q1 2026), $331,801 (Q4 2025) and $170,896 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn |
| 10 | Immix Biopharma | 692.47 Mn | 692.47 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 45,772.00 |
| Mar 31, 2026 | 193,715.00 |
| Dec 31, 2025 | 331,801.00 |
| Sep 30, 2025 | 170,896.00 |
| Jun 30, 2025 | 52,940.00 |
| Mar 31, 2025 | 127,367.00 |
| Dec 31, 2024 | 129,567.00 |
| Sep 30, 2024 | 43,341.00 |
| Jun 30, 2024 | 67,806.00 |
| Mar 31, 2024 | 122,594.00 |
| Dec 31, 2023 | 101,007.00 |
| Sep 30, 2023 | 99,603.00 |
| Dec 31, 2022 | 438,196.00 |
| Mar 31, 2022 | 9,407.00 |
| Dec 31, 2021 | 9,099.00 |
| Dec 31, 2020 | 342,837.00 |
API Access
Immix Biopharma Other Accumulated Expenses API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=IMMX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "other-accumulated-expenses", "ticker": "IMMX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=IMMX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();